Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your experience. Save up to 40% More details

5 Stocks Leading The Race To Deliver A COVID-19 Vaccine

By (Jesse Cohen/ MarketsMay 20, 2020 05:44
5 Stocks Leading The Race To Deliver A COVID-19 Vaccine
By (Jesse Cohen/   |  May 20, 2020 05:44
Saved. See Saved Items.
This article has already been saved in your Saved Items

News on progress in developing a potential COVID-19 vaccine has had a powerful influence on volatile market sentiment as of late.

With more than 100 vaccines currently in various stages of development worldwide and eight in clinical trials according to the World Health Organization, a slew of biotechnology and pharmaceutical companies are racing to deliver a vaccine for COVID-19, which has infected nearly 5 million people worldwide and killed more than 323,341.

Here are five companies showing promise in developing a vaccine:

1. Moderna

  • Vaccine: mRNA-1273
  • Development: Phase 1 trial complete, Phase 2 trial set to start

Moderna (NASDAQ:MRNA), whose stock soared 19.96% on Monday after the company shared news of the success of its Phase 1 vaccine trial, is a biotechnology company focused on the discovery and development of drugs and vaccines which contain genetic material called messenger RNA, or mRNA.

Shares have surged an impressive 266% so far in 2020, with investors betting on the company to emerge as one of the leaders in delivering a COVID-19 vaccine.

Moderna Daily Chart
Moderna Daily Chart

The Cambridge, Massachusetts-based firm has been in focus this week after sharing a press release May 18th announcing positive data from its Phase 1 human trial for its COVID-19 vaccine candidate, mRNA-1273. The trial included 45 participants, 8 of whom developed antibodies against the virus.

The company, which has been fast-tracking work with the National Institutes of Health to develop a vaccine, is the first to share results on human trial testing of a potential coronavirus vaccine.

Despite drawing criticism for failing to publish the complete data mentioned in the press release and subsequent investigation into these concerns by investors, the U.S. Food and Drug Administration has already given Moderna approval for a Phase 2 trial, which will include 600 participants. The company said it then expects to begin a Phase 3 trial in July, pending regulatory approval.

If the vaccine is found to be effective and safe to use, it could be ready for the market in early 2021, the Moderna reported.

2. Inovio Pharmaceuticals

  • Vaccine: INO-4800
  • Development: Phase 1 trial, Phase 2 set for later this summer

Inovio Pharmaceuticals (NASDAQ:INO) is a late-stage biotechnology company focused on the discovery, development, and commercialization of synthetic DNA immunotherapies and vaccines for treating cancers and infectious diseases.

Inovio's stock is up about a whopping 220% year-to-date. It is widely considered to be one of the front-runners among companies developing a COVID-19 vaccine.

INO Chart
INO Chart

The Pennsylvania-based biotech firm is currently running a Phase 1 clinical trial for INO-4800 on 40 healthy adult volunteers, making it the second potential COVID-19 vaccine to undergo human testing after Moderna's offering.

Preliminary Phase 1 data is due in late June and Phase 2 and 3 clinical trials are planned for later this summer, pending regulatory approval.

Inovio reported disappointing first-quarter results earlier this month, with both earnings and revenue missing forecasts. Despite the weak results, investors were excited to hear that Inovio continues to move rapidly through the early stages of the development of its COVID-19 vaccine.

3. Novavax

  • Vaccine: NVX-CoV2373
  • Development: Preclinical

Novavax (NASDAQ:NVAX) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of vaccines and adjuvants. Through its recombinant nanoparticle vaccine technology, it produces vaccine candidates to respond to both known and newly emerging diseases.

Shares of the high-flying Gaithersburg, Maryland-based biotech company are up a staggering 1,245% year-to-date amid bullish bets its coronavirus vaccine candidate will materialize into a major revenue source in the years ahead.

Novavax Daily Chart
Novavax Daily Chart

Novavax topped Wall Street expectations for the first quarter when it reported a loss of 58 cents per share on revenue of $3.4 million earlier this month. Analysts were expecting a loss of 69 cents per share and revenue of $1.9 million.

More importantly, the biotech company announced in its earnings release that the Oslo-based nonprofit Coalition for Epidemic Preparedness Innovations will invest $384 million to advance the clinical development of its SARS-CoV-2 vaccine candidate, NVX-CoV2373.

Novavax plans to start human trials in May with preliminary results expected in July.

Honorable Mentions

4. Johnson & Johnson

  • Vaccine: Ad26 SARS-CoV-2
  • Development: Phase 1 trial planned for September

Johnson & Johnson (NYSE:JNJ) began researching vaccine candidates in January, as soon as the COVID-19 sequence became available.

Johnson & Johnson Daily Chart
Johnson & Johnson Daily Chart

A Phase 1 clinical trial of the novel coronavirus vaccine is planned for September, with data regarding safety and efficacy available by the end of the year. If all goes accordingly, the vaccine could be ready “for emergency use” in early 2021.

As part of this commitment, Johnson & Johnson will scale up its manufacturing capacity in the U.S. and other countries in order to enable the supply of more than 1 billion doses of the vaccine when it is ready.

5. Pfizer

  • Vaccine: BNT162
  • Development: Clinical trials

Pharmaceutical giant Pfizer (NYSE:PFE), which is working alongside German drugmaker BioNTech (NASDAQ:BNTX) to develop a coronavirus vaccine, says it should have initial data from its stage one clinical trial in mid-to-late June.

Pfizer Daily Chart
Pfizer Daily Chart

The New York-based company is currently testing four different vaccine variations. If one or two variations indicate success, Pfizer will ramp up clinical trials, and then in September launch a broad large-scale study with thousands of participants.

CEO Albert Bourla said that if the vaccine proves to be safe, the company “will be able to deliver millions of doses in the October time frame.” The company plans to produce hundreds of millions of doses in 2021, he added.

5 Stocks Leading The Race To Deliver A COVID-19 Vaccine

Related Articles

5 Stocks Leading The Race To Deliver A COVID-19 Vaccine

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at’s discretion.

Write your thoughts here
Are you sure you want to delete this chart?
Post also to:
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (2)
Ed Crain
Ed Crain May 20, 2020 10:59
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Cohen get paid to recommend stocks? It can't be because he knows anything that he's talking about. Otherwise he'd be a multibillionaire. Proof is in the portfolio people!
Pat Ditomasso
Pat Ditomasso May 20, 2020 6:36
Saved. See Saved Items.
This comment has already been saved in your Saved Items
revive therapuetics co . doin work with a drug , bucillamine
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
Sign up with Email